Correct usage and dosage of dabrafenib/dabrafenib: How to take it efficiently?

Dabrafenib is a targeted therapy drug targeting BRAF mutations and is widely used to treat BRAF mutation-positive melanoma, thyroid cancer, non-small cell lung cancer (NSCLC) and other tumors. By inhibiting the activity of BRAF V600E mutant kinase, it prevents the proliferation of cancer cells and thereby delays the progression of the disease. Correct usage and dosage are crucial to ensure the efficacy of the drug and reduce side effects.

According to the drug package insert, the usual recommended adult dose of dabrafenib is 150 mg twice daily. Take it at least 1 hour before meals and 2 hours after meals to avoid irritation to the gastrointestinal tract. If you miss a dose, you should try to take it on the day you remember, but you should not take it again at the time of your next dose. If the two doses are at similar times, it is recommended to skip the missed dose and continue taking the dose at the regular time.

During treatment, the dose of dabrafenib may be adjusted based on patient tolerance. If a patient experiences significant adverse reactions, the doctor may choose to lower the dose or temporarily discontinue the drug. For example, when severe side effects such as rash, fever, nausea, etc. occur, it is usually recommended to suspend treatment and resume treatment after symptoms subside, or to adjust the dose according to the patient's condition. During drug treatment, patients need to undergo regular physical examinations, especially monitoring of liver function, kidney function and blood routine, in order to detect potential side effects in time.

In addition, dabrafenib is often used in combination with other drugs, such as trametinib (Trametinib), for the treatment of BRAF V600E mutated melanoma and non-small cell lung cancer. During combined treatment, patients need to follow the doctor's guidance and adjust the dosage of the two drugs to achieve the best therapeutic effect.

Reference materials:https://go.drugbank.com/drugs/DB08912